General MedicationsORALGeneric

SITAGLIPTIN PHOSPHATE; METFORMIN HYDROCHLORIDE

Standard Dose

50MG;500MG

Max Dose

Refer to approved labeling

Primary Use

Marketing status: None (Tentative Approval)

Summary

Approval overview SITAGLIPTIN PHOSPHATE; METFORMIN HYDROCHLORIDE is listed in Drugs@FDA under application 202365 (ANDA).

Marketing status: None (Tentative Approval) Active ingredient SITAGLIPTIN PHOSPHATE; METFORMIN HYDROCHLORIDE Form and strength TABLET;ORAL - 50MG;500MG Sponsor WATSON LABS INC Submission history Latest submission status date: 2015-10-30 00:00:00.

Structured Monograph

Clinical summary

Approval overview SITAGLIPTIN PHOSPHATE; METFORMIN HYDROCHLORIDE is listed in Drugs@FDA under application 202365 (ANDA). Marketing status: None (Tentative Approval) Active ingredient SITAGLIPTIN PHOSPHATE; METFORMIN HYDROCHLORIDE Form and strength TABLET;ORAL - 50MG;500MG Sponsor WATSON LABS INC Submission history Latest submission status date: 2015-10-30 00:00:00. Submission type: ORIG.

Monitoring

• Marketing status: None (Tentative Approval)

Interaction Notes

No interaction notes stored yet.